Company / Net Income
Gilead Sciences Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$8.5B
FY2025
5-year range
$123.0M / $8.5B
FY2021-FY2025
Trend
+1672.9%
vs FY2024
Sector context
#5 of 216
Health Care
What the data says
Net Income changed +1673% YoY in FY2025, a notable deviation from the 9-year average annual change of +1176%.
Based on SEC 10-K filings.
$8.5B in FY2025 with a 5-year CAGR of +133.3%. Top quartile in the Health Care sector.
Improved from $6.2B to $8.5B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +310.5%
- 5-Year CAGR
- +133.3%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 216This company $8.5B Sector average $454.3M
▼
+1773.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +133.3%, indicating consistent growth.
- In FY2025, net income increased 1672.9% year-over-year.
- Ranks #5 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2017.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.5B | +1672.9% |
| FY2024 | $480.0M | -92.3% |
| FY2023 | $6.2B | +4961.0% |
| FY2022 | $123.0M | -97.7% |
| FY2021 | $5.4B | +4278.9% |
| FY2020 | $123.0M | -97.3% |
| FY2019 | $4.6B | -65.7% |
| FY2018 | $13.5B | -25.4% |
| FY2017 | $18.1B | +49.6% |
| FY2016 | $12.1B | -33.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026